American Oncology Network AI Stock Analysis
Want to see AONC full AI Analyst Report?
American Oncology Network (AONC) AI Stock Analysis
American Oncology Network
(Other OTC:AONC)
The overall score of 39 reflects high risk due to weak financial fundamentals, including unprofitability, negative cash flow, and high leverage, combined with a bearish technical trend. Valuation also remains poor. While revenue growth offers a glimmer of potential, significant challenges persist.
American Oncology Network (AONC) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $672.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,930
- Price to Earnings (P/E)
- -33.3
- Beta (1Y)
- 0.49
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- US
- Employees
- 1,914
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Care Facilities
American Oncology Network Business Overview & Revenue Model
Company Description
American Oncology Network, Inc. engages in the provision of community-based oncology management. The firm provides various services to patients, including laboratory services for routine and specialized testing, in-house professional and technical pa...
How the Company Makes Money
AON’s revenue model is based on providing management and support services to affiliated/partner oncology practices and, where applicable, operating or enabling ancillary services tied to outpatient cancer care. Key revenue streams include: (1) manage...
American Oncology Network Earnings Call Summary
The earnings call highlighted significant revenue growth and expansion through acquisitions, as well as the launch of an innovative analytics platform. However, these positives were offset by increased costs, a higher net loss, and a decrease in adjusted EBITDA.
Q1-2024 Updates
Positive Updates
Negative Updates
Company Guidance
In the first quarter of 2024, American Oncology Network (AONC) reported a revenue increase of 20% to $364.3 million, up from $303.7 million in the previous year, driven by a 12.8% rise in revenue per encounter and a 6.2% increase in patient encounters. Despite these gains, the company experienced a net loss before non-controlling interest of $24.9 million, compared to a $1.5 million loss in the prior year, with adjusted EBITDA falling to $2 million from $4 million. The cost of revenue rose to $354.9 million, primarily due to higher drug and medical supply costs, while equity-based compensation accounted for $13.3 million. AONC's strategic growth included the addition of 17 new providers and significant acquisitions, enhancing its platform with the launch of Meaningful Insights Biotech Analytics (MiBA) to improve cancer care through AI-driven insights. The company ended the quarter with a total liquidity of $132.7 million, including cash and cash equivalents of $74.9 million, and maintained an $81.3 million outstanding balance under its PNC Loan Facility.
American Oncology Network Financial Statement Overview
Summary
AONC shows strong revenue growth but faces profitability challenges, high leverage, and persistent negative cash flows. The composite score reflects these significant risks, though revenue growth provides a modest positive.
Income Statement
45NeutralBalance Sheet
30NegativeCash Flow
25Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.76B | 1.76B | 1.28B | 1.15B | 943.75M | 724.74M |
| Gross Profit | 117.85M | 117.85M | 82.80M | 95.45M | 77.96M | 66.11M |
| EBITDA | 1.81M | 1.81M | -39.35M | 23.09M | 7.85M | 25.94M |
| Net Income | -3.97M | -3.97M | -5.54M | 2.59M | -105.00K | 21.95M |
Balance Sheet | ||||||
| Total Assets | 470.33M | 470.33M | 374.45M | 326.23M | 248.30M | 49.03K |
| Cash, Cash Equivalents and Short-Term Investments | 72.64M | 72.64M | 63.93M | 36.78M | 27.35M | 25.00K |
| Total Debt | 147.37M | 147.37M | 128.32M | 127.13M | 63.69M | 0 |
| Total Liabilities | 362.32M | 362.32M | 303.74M | 264.21M | 22.26M | 24.87K |
| Stockholders Equity | 18.77M | 18.77M | -161.73M | 62.02M | 312.62M | 24.17K |
Cash Flow | ||||||
| Free Cash Flow | 53.08M | -25.90M | -30.40M | -13.98M | -34.66M | 25.02M |
| Operating Cash Flow | 74.12M | -4.94M | -18.12M | -6.78M | -26.34M | 37.24M |
| Investing Cash Flow | 824.00K | -2.41M | -35.40M | -13.99M | -333.50M | -14.67M |
| Financing Cash Flow | 46.90M | 41.66M | 55.13M | 15.35M | 335.53M | 16.26M |
American Oncology Network Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AONC, the sentiment is Positive. The current price of 23.00 is above the 20-day moving average (MA) of 20.09, above the 50-day MA of 14.56, and above the 200-day MA of 11.55, indicating a bullish trend. The MACD of 2.47 indicates Positive momentum. The RSI at 68.43 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AONC.
American Oncology Network Risk Analysis
American Oncology Network disclosed 54 risk factors in its most recent earnings report. American Oncology Network reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksAmerican Oncology Network Peers Comparison
Overall Rating
AGL56Neutral
CYH44Neutral- AONC39.3Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AGL | 56Neutral | $1.85B | -17.66 | -51.94% | ― | 2.02% | 66.99% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| CYH | 44Neutral | $311.67M | 8.30 | -2.51% | ― | -7.84% | -88.93% |
| AONC | 39Underperform | $1.05B | -33.33 | 5.56% | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AONC | American Oncology Network, Inc. Class A | 23.00 | 11.80 | 105.36% | |
| CYH | Community Health Systems | 2.24 | -0.77 | -25.58% | |
| AGL | Agilon Health Inc | 115.66 | 102.23 | 761.53% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Jan 22, 2026